NEW YORK, NY / ACCESSWIRE / June 2, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Amazon.com, Inc. (NASDAQ:AMZN)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/amazon-com-inc-loss-submission-form?prid=28049&wire=1
Lead Plaintiff Deadline: July 5, 2022
Class Period: February 1, 2019 - April 5, 2022
Allegations against AMZN include that: (i) Amazon engaged in anticompetitive conduct in its private-label business practices, including giving Amazon products preference over those of its competitors and using third-party sellers' non-public data to compete with them; (ii) the foregoing exposed Amazon to a heightened risk of regulatory scrutiny and/or enforcement actions; (iii) Amazon's revenues derived from its private-label business were in part the product of impermissible conduct and thus unsustainable; and (iv) as a result, the defendants' public statements throughout the class period were materially false and/or misleading.
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/axsome-therapeutics-inc-loss-submission-form?prid=28049&wire=1
Lead Plaintiff Deadline: July 12, 2022
Class Period: December 30, 2019 - April 22, 2022
Allegations against AXSM include that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07, the Company's medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application ("NDA") on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Spero Therapeutics, Inc. (NASDAQ:SPRO)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/spero-therapeutics-inc-loss-submission-form?prid=28049&wire=1
Lead Plaintiff Deadline: July 25, 2022
Class Period: October 28, 2021 - May 2, 2022
Allegations against SPRO include that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong